Indian Healthcare sector is at
crossroads. Challenges are
many, ranging from rising
dual disease burden –both
Communicable Disease (CD)
and Non-Communicable Disease
(NCD) burden, quality, access,
affordability, health infrastructure,
financing, rational pricing of
essential devices, trust deficit
between stakeholders, lack of clear
policies and regulatory framework.
The growing ageing population
and rise in cost of their healthcare
needs are exerting considerable
demands on the health systems.
Today, the Indian government
spends only about 1.4% of its
GDP on healthcare, which is
among the lowest globally for any
country. There is a need to focus
more on raising the investment
in healthcare in the country (PwC
Report).
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc
